Well for 1: Two years in a row, 2016 and 2017, they were profitable and they added an additional $3 million and $2 million, respectively, in annual net revenues from the previous year. In 2018 they complete acquisitions at a cost, engineer new first of it's kind TelePharmacy platform technology at a cost, and see declines in reimbursement rates affecting profit, as did CVS, WALGREENS, ETC.
Well for 2: They are in process of becoming SEC compliant so no 8-K is required. Lol
EOM. LOL